

## Special Issue

# A Saga of Vaccine Development: Past, Present, and Future

### Message from the Guest Editors

The Special Issue “A Saga of Vaccine Development: Past, Present, And Future” aims to provide a forum for review articles that highlights vaccines in all their glory. In this Special Issue, we focus on vaccines in different times and places—the known past with its success and failures stories, the uncertain present with ongoing global pandemics, and the unknown but optimistic future that lies ahead. The topic of interest include, but are not limited to, review articles that describe interventions in vaccines:

- Exploratory phase in vaccine development;
- Preclinical phase in vaccine development;
- Clinical studies in vaccine development;
- Genetic engineering in vaccine development;
- Live attenuated virus vaccine;
- Inactivated vaccines;
- Subunit vaccines;
- Nucleic acid vaccines;
- New target for vaccination;
- Immunization;
- Vaccine platforms and delivery systems;
- Vaccines in the age current global pandemic, COVID 19.

We look forward to receiving your contributions.

---

### Guest Editors

Dr. Suman Chowdhury

Department of Pharmacology, Physiology, Neuroscience, NJMS,  
Rutgers University, Newark, NJ 07103, USA

Dr. Ranjeet Kumar

Department of Pharmacology, Physiology, Neuroscience, NJMS,  
Rutgers University, Newark, NJ 07103, USA

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/155319](https://mdpi.com/si/155319)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).